Cellnovo Launches New Mobile App that Connects Directly to CGM Data via HealthKit

Cellnovo mobile app
Image: Cellnovo

Cellnovo Group, a French MedTech company announced the launch of the Cellnovo Monitoring App, which enables direct access continuous glucose monitoring (CGM) data via the HealthKit in real time. The mobile application, available on App stores worldwide, provides real-time diabetes management data from the Cellnovo Gen 3 System, including blood glucose readings, insulin intake, activity records and carbohydrate data.

Read more Senseonics Gets FDA Approval for Long-Term Implantable CGM Eversense

Cellnovo’s connected diabetes management platform is composed of an insulin micro-pump and communicates via Bluetooth with a locked-down Android smartphone, reports Business Wire.

“We are pleased to be able to offer patients the ability to view CGM data directly on their personal smartphones using the Cellnovo Monitoring App. This is a natural extension of the Cellnovo Diabetes Management Platform, facilitating access to real-time diabetes management data and contributing to an increasingly seamless user experience,” said Sophie Baratte, Chief Executive Officer of Cellnovo.

app

Cellnovo Group is global innovative medical technology company supporting the needs and desires of people with type 1 diabetes. Cellnovo has developed and markets a novel diabetes management system, which is a connected platform that aims to make life easier for people with type 1 diabetes. Cellnovo’s insulin delivery system comprises a discreet, wearable micro-pump that communicates via Bluetooth® Low Energy with a locked-down AndroidTM smartphone. This unique system allows optimal management of insulin dosing and delivery while ensuring freedom of movement and peace of mind.

Read more Medtronic’s Smartphone-Connected CGM System Gets FDA Approval

Thanks to the transmission of data in real time, the patient’s status can be seamlessly monitored by family members and healthcare professionals. Cellnovo is currently participating in several major Artificial Pancreas projects with TypeZero, PEPPER and Diabeloop, to develop fully automated, closed-loop insulin delivery systems.